01/23/23 4:15 PMNasdaq : AXLA covid-19Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID FatigueAxcella will be meeting with the MHRA in the near term to discuss the Innovative Licensing and Access Pathway application. The company further reported submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for a Phase 2 b/3 trial. Recent estimates indicate that 15-20% of Americans with COVID have persisting health...RHEA-AIneutral
12/14/22 8:01 PMNasdaq : AXLA Axcella Announces Program Reprioritization and Corporate RestructuringAxcella Therapeutics, a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs. “The strategic process we initiate today prioritizes...RHEA-AIpositive
11/03/22 9:59 AMNasdaq : AXLA conferencesAxcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual MeetingAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases...RHEA-AIneutral
11/01/22 7:00 AMNasdaq : AXLA earningsAxcella Reports Third Quarter Financial Results and Provides Business UpdateAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. “This has been an extremely exciting period for Axcella,”...RHEA-AIneutral
10/27/22 8:30 AMNasdaq : AXLA conferencesearningsAxcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that it plans to report its third quarter 2022 financial results and other business updates on November 1, 2022. The company will host a conference call at...RHEA-AIneutral
10/14/22 1:24 PMNasdaq : AXLA conferencesAxcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor ConferenceAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6 th Annual NASH Investor Conference taking place...RHEA-AIneutral
10/13/22 8:00 AMNasdaq : AXLA offeringmanagementAxcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board MembersThe Shares were offered pursuant to a shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission and declared effective by the SEC on June 12, 2020. A final prospectus supplement, which contains additional information relating to the offering, has been filed with the SEC and is available on the SEC’ s website at...RHEA-AIneutral
09/29/22 6:00 AMNasdaq : AXLA clinical trialAxcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today reported interim results from their ongoing global Phase 2 b randomized, double-blind, placebo-controlled, dose ranging EMMPACT study to evaluate the safety,...RHEA-AIpositive
09/12/22 8:00 AMNasdaq : AXLA conferencesAxcella Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference taking place September...RHEA-AIneutral
08/12/22 7:30 AMNasdaq : AXLA earningsAxcella Reports Second Quarter Financial Results and Provides Business UpdateAxcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update. Cash Position: As of June 30, 2022, cash, cash equivalents, and...RHEA-AIneutral